Latvian Institute of Organic Synthesis Installs InSyTe FLECT/CT Preclinical Imaging System
TriFoil Imaging is excited to announce that the research facility at Latvian Institute of Organic Synthesis (IOS), Latvia, has installed an InSyTe FLECT/CT.
Chatsworth, CA, April 29, 2015 --(PR.com)-- TriFoil Imaging is excited to announce that the research facility at Latvian Institute of Organic Synthesis (IOS), Latvia, has installed an InSyTe FLECT/CT. This system was sold through TriFoil Imaging’s distributor in the CIS Countries and Scandinavia, GenMedica-Baltic. The system was installed under the operation of the IOS Laboratory of Pharmaceutical Pharmacology, Head Prof. Maija Dambrova, for drug discovery research.
The Fluorescence emission and X-ray computer tomography equipment was delivered to the IOS to upgrade the research infrastructure in the 7th EU Framework Program project. States Prof. Maija Dambrova: “Strengthening the research and innovative capacities of the Latvian Institute of Organic Synthesis, the leading Baltic regional centre for drug discovery,” InnovaBalt.
TriFoil Imaging is enthusiastic that IOS, the coordinator of the InnovaBalt project and a partner in several European research project consortia has selected tomographic fluorescent imaging for its molecular imaging studies. States Staf C. van Cauter, VP Global sales and Business Development: “This installation further extends our global network of researchers committing to TriFoil’s unique Fluorescence Emission Computed Tomography (FLECT) technique.”
They are happy to bring State of the Art technology to IOS by supplying tomography systems manufactured by the world’s leading designer and manufacturer Trifoil Imaging. CEO and Director of GenMedica-Baltic, Vadims Vakarjuks, states: “The necessity for preclinical research has been growing rapidly in the last decade to minimize the gap between in vitro and in vivo experiments. Novel drug components need to be tested before applying for clinical use and this process is becoming more and more standardized and used for routine research. We can observe a high interest in preclinical research and its big ascent for IOS to be a leading drug discovery center in the Baltic region."
The IOS Laboratory of Pharmaceutical Pharmacology is interested in mechanisms behind the action of novel cardioprotective, neuroprotective and anti-atherosclerotic compounds as well as pathogenesis of ischemia-reperfusion injury, local inflammation and atherosclerosis. Prof. Dambrova states: “With InSyTe FLECT/CT 360º system we will be able to study true anatomical displacement of small animals and accurately measure fluorophore concentrations throughout the region of interest. We will monitor the progression of atherosclerosis in aorta, ischemia-reperfusion or traumatic injury in the brain, permeability of vasculature and inflammation. In addition, we can evaluate the efficacy of the treatment when studying novel compounds. InSyTe FLECT/CT system could be used also by other laboratories/groups of IOS that are or will be interested in studying angiogenesis, apoptosis, cancer or infectious diseases.”
TriFoil Imaging’s state-of-the-art digital molecular imaging products include the Triumph II, a tri-modality PET/SPECT/CT system, the eXplore CT-120 In-vivo Micro CT scanner, the LabPET/MRI system with integrated self-shielded cryogen-free 3.0T MRI and the InSyTe Series, the first pre-clinical bench-top nuclear and optical imaging systems with in-line CT. There are now over 319 installations worldwide.
About the Latvian Institute of Organic Synthesis, Riga
The core competences of IOS are medicinal chemistry and innovative drug discovery with outstanding expertise in molecular modeling, organic synthesis, medicinal chemistry and preclinical drug development for the treatment of cancer, cardiovascular diseases and CNS disorders. The IOS has over 55 years experience in drug discovery and is proud to be an inventor and co-inventor of 18 original approved drugs and more than 70 original preparation methods of known medicines. With ≈115 PhD’s Latvian IOS is the leading research centre of organic synthesis, medicinal chemistry and drug discovery in the Baltic region. IOS is located in Riga and possesses about 2400m2 of equipped laboratory space for organic synthesis, physical organic chemistry and analytical chemistry as well as pharmacology. Presently IOS has on-going projects with 11 pharmaceutical companies. Together with business partners more than 270 patents have been filed in the last 5 years.
About TriFoil Imaging
Leading research laboratories around the world depend on TriFoil Imaging (formerly Gamma Medica – Ideas Pre-Clinical) technology to meet all their advanced in-vivo molecular imaging needs. Triumph is the world’s first tri-modality system (including PET, SPECT, and CT) to offer the highest quality and the best value by combining three modalities all in one reliable and easy-to-use system.
Founded in 2001 and now owned by Capital Resource Partners, TriFoil is headquartered in Chatsworth, California. Please visit Trifoil Imaging's website to learn more.
About GenMedica:
Specializes in laboratory consumable supplies for academic and commercial science.
The Fluorescence emission and X-ray computer tomography equipment was delivered to the IOS to upgrade the research infrastructure in the 7th EU Framework Program project. States Prof. Maija Dambrova: “Strengthening the research and innovative capacities of the Latvian Institute of Organic Synthesis, the leading Baltic regional centre for drug discovery,” InnovaBalt.
TriFoil Imaging is enthusiastic that IOS, the coordinator of the InnovaBalt project and a partner in several European research project consortia has selected tomographic fluorescent imaging for its molecular imaging studies. States Staf C. van Cauter, VP Global sales and Business Development: “This installation further extends our global network of researchers committing to TriFoil’s unique Fluorescence Emission Computed Tomography (FLECT) technique.”
They are happy to bring State of the Art technology to IOS by supplying tomography systems manufactured by the world’s leading designer and manufacturer Trifoil Imaging. CEO and Director of GenMedica-Baltic, Vadims Vakarjuks, states: “The necessity for preclinical research has been growing rapidly in the last decade to minimize the gap between in vitro and in vivo experiments. Novel drug components need to be tested before applying for clinical use and this process is becoming more and more standardized and used for routine research. We can observe a high interest in preclinical research and its big ascent for IOS to be a leading drug discovery center in the Baltic region."
The IOS Laboratory of Pharmaceutical Pharmacology is interested in mechanisms behind the action of novel cardioprotective, neuroprotective and anti-atherosclerotic compounds as well as pathogenesis of ischemia-reperfusion injury, local inflammation and atherosclerosis. Prof. Dambrova states: “With InSyTe FLECT/CT 360º system we will be able to study true anatomical displacement of small animals and accurately measure fluorophore concentrations throughout the region of interest. We will monitor the progression of atherosclerosis in aorta, ischemia-reperfusion or traumatic injury in the brain, permeability of vasculature and inflammation. In addition, we can evaluate the efficacy of the treatment when studying novel compounds. InSyTe FLECT/CT system could be used also by other laboratories/groups of IOS that are or will be interested in studying angiogenesis, apoptosis, cancer or infectious diseases.”
TriFoil Imaging’s state-of-the-art digital molecular imaging products include the Triumph II, a tri-modality PET/SPECT/CT system, the eXplore CT-120 In-vivo Micro CT scanner, the LabPET/MRI system with integrated self-shielded cryogen-free 3.0T MRI and the InSyTe Series, the first pre-clinical bench-top nuclear and optical imaging systems with in-line CT. There are now over 319 installations worldwide.
About the Latvian Institute of Organic Synthesis, Riga
The core competences of IOS are medicinal chemistry and innovative drug discovery with outstanding expertise in molecular modeling, organic synthesis, medicinal chemistry and preclinical drug development for the treatment of cancer, cardiovascular diseases and CNS disorders. The IOS has over 55 years experience in drug discovery and is proud to be an inventor and co-inventor of 18 original approved drugs and more than 70 original preparation methods of known medicines. With ≈115 PhD’s Latvian IOS is the leading research centre of organic synthesis, medicinal chemistry and drug discovery in the Baltic region. IOS is located in Riga and possesses about 2400m2 of equipped laboratory space for organic synthesis, physical organic chemistry and analytical chemistry as well as pharmacology. Presently IOS has on-going projects with 11 pharmaceutical companies. Together with business partners more than 270 patents have been filed in the last 5 years.
About TriFoil Imaging
Leading research laboratories around the world depend on TriFoil Imaging (formerly Gamma Medica – Ideas Pre-Clinical) technology to meet all their advanced in-vivo molecular imaging needs. Triumph is the world’s first tri-modality system (including PET, SPECT, and CT) to offer the highest quality and the best value by combining three modalities all in one reliable and easy-to-use system.
Founded in 2001 and now owned by Capital Resource Partners, TriFoil is headquartered in Chatsworth, California. Please visit Trifoil Imaging's website to learn more.
About GenMedica:
Specializes in laboratory consumable supplies for academic and commercial science.
Contact
TriFoil Imaging
Beth Silverman
818-709-2468
trifoilimaging.com
Beth Silverman
818-709-2468
trifoilimaging.com
Contact
Categories